Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology is viewed favorably because its HDV franchise is nearing an inflection, with SOLSTICE showing 88% HDV RNA target-not-detected at Week 96 and roughly 90% of patients below 10 IU/mL HBsAg, supporting confidence ahead of Phase 3 ECLIPSE 1 data in 4Q26. Its PRO-XTEN oncology platform is also gaining credibility after the Astellas collaboration and VIR-5500 monotherapy dose escalation in 58 patients produced no dose-limiting toxicities, no maximum tolerated dose reached, 82% PSA50, and 53% PSA90 at or above 3,000 µg/kg, with a modeled probability of success raised to 40% from 20%. The company’s financial outlook is strengthened by a projected ramp from $259.3 million in 2026E revenue to $423.5 million in 2030E, plus milestone and royalty potential, while its leadership additions and robust cash position support execution across both franchises.

Vir Biotechnology is fundamentally challenged by a narrow revenue base that still relies mainly on license rights and grants, while much of its value depends on clinical assets that have not yet proven commercial viability. The company’s HDV opportunity is constrained by a small addressable pool of roughly 65,000 actively viremic U.S. patients in 2030E and 71,000 by 2039E, plus boxed-warning safety concerns, no FDA approval precedent in HDV, and rising competition from GILD’s bulevirtide and brelovitug. Its broader pipeline also carries high execution risk, and expected gross equity raises of $300M-$350M annually from 2028E-2029E imply dilution while operating losses remain meaningful.